Astellas Pharma Inc

ALPMY-O

Analysis and Opinions about ALPMY-O

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
November 27, 2020
(A Top Pick Nov 08/19, Down 7%) All pharmas face a "patent cliff" where they drugs they developed are about to go generic, so companies need to develop new drugs or buy companies. Theirs ended in March. This is going from a value into a growth stock. They now have 3 drugs in the pipeline, including a blader cancer one, a prostate one, and one for severe menopause which has great potential and awaiting approval. The stock hasn't done much, but the potential is high.
Show full opinionHide full opinion
(A Top Pick Nov 08/19, Down 7%) All pharmas face a "patent cliff" where they drugs they developed are about to go generic, so companies need to develop new drugs or buy companies. Theirs ended in March. This is going from a value into a growth stock. They now have 3 drugs in the pipeline, including a blader cancer one, a prostate one, and one for severe menopause which has great potential and awaiting approval. The stock hasn't done much, but the potential is high.
TOP PICK
TOP PICK
November 8, 2019
It has been a long time since they have held a Japanese company. They are near the end of their "patent cliff", when the share price is negatively impacted by patent protection ending. They specialize in new cancer drugs and have a lot of new patents coming forward. Japan and healthcare shares are improving. Yield 2.17% (Analysts’ price target is $19.40)
Show full opinionHide full opinion
It has been a long time since they have held a Japanese company. They are near the end of their "patent cliff", when the share price is negatively impacted by patent protection ending. They specialize in new cancer drugs and have a lot of new patents coming forward. Japan and healthcare shares are improving. Yield 2.17% (Analysts’ price target is $19.40)
Showing 1 to 2 of 2 entries
  • «
  • 1
  • »

Astellas Pharma Inc(ALPMY-O) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for Astellas Pharma Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Astellas Pharma Inc(ALPMY-O) Frequently Asked Questions

What is Astellas Pharma Inc stock symbol?

Astellas Pharma Inc is a OTC stock, trading under the symbol ALPMY-O on the (). It is usually referred to as or ALPMY-O

Is Astellas Pharma Inc a buy or a sell?

In the last year, 1 stock analyst published opinions about ALPMY-O. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is PAST TOP PICK. Read the latest stock experts' ratings for Astellas Pharma Inc.

Is Astellas Pharma Inc a good investment or a top pick?

Astellas Pharma Inc was recommended as a Top Pick by Norman Levine on 2020-11-27. Read the latest stock experts ratings for Astellas Pharma Inc.

Why is Astellas Pharma Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Astellas Pharma Inc worth watching?

1 stock analyst on Stockchase covered Astellas Pharma Inc In the last year. It is a trending stock that is worth watching.

What is Astellas Pharma Inc stock price?

On , Astellas Pharma Inc (ALPMY-O) stock closed at a price of $.